- Open Access
ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function
© Christie et al; licensee BioMed Central Ltd. 2008
Received: 12 July 2008
Accepted: 01 October 2008
Published: 01 October 2008
Ovarian adenocarcinoma is not generally discovered in patients until there has been widespread intraperitoneal dissemination, which is why ovarian cancer is the deadliest gynecologic malignancy. Though incompletely understood, the mechanism of peritoneal metastasis relies on primary tumor cells being able to detach themselves from the tumor, escape normal apoptotic pathways while free floating, and adhere to, and eventually invade through, the peritoneal surface. Our laboratory has previously shown that the Golgi glycosyltransferase, ST6Gal-I, mediates the hypersialylation of β1 integrins in colon adenocarcinoma, which leads to a more metastatic tumor cell phenotype. Interestingly, ST6Gal-I mRNA is known to be upregulated in metastatic ovarian cancer, therefore the goal of the present study was to determine whether ST6Gal-I confers a similarly aggressive phenotype to ovarian tumor cells.
Three ovarian carcinoma cell lines were screened for ST6Gal-I expression, and two of these, PA-1 and SKOV3, were found to produce ST6Gal-I protein. The third cell line, OV4, lacked endogenous ST6Gal-I. In order to understand the effects of ST6Gal-I on cell behavior, OV4 cells were stably-transduced with ST6Gal-I using a lentiviral vector, and integrin-mediated responses were compared in parental and ST6Gal-I-expressing cells.
Forced expression of ST6Gal-I in OV4 cells, resulting in sialylation of β1 integrins, induced greater cell adhesion to, and migration toward, collagen I. Similarly, ST6Gal-I expressing cells were more invasive through Matrigel.
ST6Gal-I mediated sialylation of β1 integrins in ovarian cancer cells may contribute to peritoneal metastasis by altering tumor cell adhesion and migration through extracellular matrix.
The α2–6 linkage of sialic acids to N-acetyllactosamine structures (Galβ1–4GlcNAc) is a Golgi-mediated process facilitated by the enzyme, β-galactoside α2–6-sialyltransferase (ST6Gal-I). Variant α2–6 sialylation can have a wide array of biologic and pathogenic consequences, including alterations in immune response and embryogenesis, as well as a role in the development and progression of some cancers . There are several recognized substrates upon which ST6Gal-I is known to act: β1 integrin , E-selectin, ICAM-1, and VCAM-1 . Perturbation of normal ST6Gal-I functioning fundamentally alters cell behavior by modulating normal cell interactions with the surrounding environment.
The overexpression of ST6Gal-I is well documented in several diverse cancer types. These cancers include: colorectal , cervical , breast , hepatocellular , and certain cancers of the head and neck . ST6Gal-I is upregulated by oncogenic ras [9–11] thus accounting for the increased enzyme expression in the various tumor types . Our group has reported that forced expression of ST6Gal-I in SW48 colonocytes, which lack endogenous sialyltransferase activity, caused increased binding to collagen I and laminin, and increased cell motility . This change in cell behavior was shown to be a consequence of the hypersialylation of the β1 integrin. Though incompletely understood, β1 hypersialylation could modify integrin-dependent cell responses through a change in receptor conformation, by masking functional domains within the integrin heterodimer, by affecting integrin interaction with other membrane bound proteins or glycolipids, or by another, as yet, unrecognized mechanism . Lin and colleagues demonstrated that forced expression of ST6Gal-I in MDA-MB-435 human mammary carcinoma cells resulted in increased adhesion to collagen IV, reduced cell-cell adhesion, and increased capacity for invasion . Conversely, introduction of antisense oligonucleotides to ST6Gal-I in colon cancer cells reduced the cells' ability to form colonies and to invade . Taken in sum, these results suggest that overexpression of ST6Gal-I results in a phenotype consistent with aggressive metastasis. In fact, increased tumor levels of ST6Gal-I have been correlated with poorer patient prognosis [15, 6], though there are also reports suggesting that ST6Gal-I activity is not predictive of outcome [16, 17].
The role of ST6Gal-I in ovarian carcinoma has not been as clearly defined as its effect in some other tumors, namely colon and breast. Nonetheless, there are recent data indicative of the emerging attention to the importance of sialylation in ovarian cancer. High-throughput techniques have yielded evidence that ST6Gal-I is up-regulated in epithelial ovarian malignancy. For example, proteomic analysis revealed α2–6 sialylation to be proportionally favored over α2–3 sialylation . This mirrors the results of Wang and colleagues who showed increased mRNA levels of ST6Gal-I and decreased levels of the α2–3 sialyltransferase, ST3Gal-VI in ovarian cancer . These enzymes can compete for the linkage of sialic acids to terminal Galβ1–4GlcNAc, and thus the findings indicate that there is preference for α2–6 sialylation in the ovary with malignant transformation. Despite these observed differences in ST6Gal-I mRNA and global cell surface sialylation, a direct examination of ST6Gal-I protein in ovarian tumor cells has not previously been attempted. As well, there is limited information regarding the functional consequences of ST6Gal-I upregulation in ovarian carcinoma. Casey and colleagues treated OVCAR5 ovarian carcinoma cells with neuraminidase enzyme to remove sialic acids and found that this decreased migration toward fibronectin, and reduced invasion through Matrigel . However, the neuraminidase enzyme does not discriminate between α2–6 and α2–3-linked sialic acids, and therefore the changes in cell migration and invasion could not be directly ascribed to ST6Gal-I activity.
In the present study, we screened three separate ovarian carcinoma cell lines for endogenous expression of ST6Gal-I, and found that two of these were positive for ST6Gal-I protein. The third, the OV4 cell line, had negligible levels of the enzyme and therefore, to assess the effects of α2–6 sialylation on promoting the tumor cell phenotype, we forced ST6Gal-I expression and evaluated integrin-dependent cell behaviors. ST6Gal-I expression, with consequent β1 integrin hypersialylation, induced increased adhesion to collagen I, migration toward collagen I, and invasiveness through Matrigel. Our results suggest a potential role for variant sialylation in the dissemination of ovarian carcinoma.
Ovarian carcinoma cell lines
The ovarian carcinoma cell line SKOV3 was generously gifted to us by Dr. Janet Price (MD Anderson, Houston, TX), whereas the OV4 cell line was a generous gift from Dr. Timothy Eberlein (Harvard, Cambridge, MA). The PA1 cell line was purchased commercially through ATCC (Manassas, VA). PA1 cells were cultured and grown in Eagle's minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT) and penicillin, streptomycin, and amphotericin B. OV4 and SKOV3 cells were cultured and grown in Dulbecco's modified Eagle's MEM/Ham's F-12 50:50 (DMEM/F12) supplemented with 10% FBS, penicillin, streptomycin, and amphotericin B. Cells were maintained at 37°C in 5% CO2 and passaged two to three times per week.
Cells were lysed in buffer composed of 50 mM Tris-HCl (pH 7.4) containing 1% Triton X-100, and a protease inhibitor cocktail (Roche Applied Bioscience). Protein concentrations of the lysates were determined using a modified Bradford Assay (Sigma, St. Louis, MO). Proteins were resolved by reducing SDS-PAGE, and transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% nonfat dry milk in TBS containing 0.05% Tween 20 (TBST). Primary antibodies were then added to the membranes for incubation, with antibody against ST6Gal-I (a monoclonal generated by the UAB Hybridoma Core Facility), β1 integrin (Transduction Laboratories, Lexington, KY), or the V5 epitope (Invitrogen, Carlsbad, CA). Membranes were then washed and incubated with horseradish peroxidase-coupled secondary antibody (Amersham, Piscataway, NJ). The labeled proteins were visualized with enhanced chemiluminescence, and subsequent images were scanned with a Hewlett-Packard Scanjet 5470 c (Wilmington, DE).
SNA-1 lectin affinity assay
Cell lysates were incubated overnight at 4°C with rotation with 100 μg/mL of the α2–6 sialic acid-specific lectin, SNA-1, conjugated to agarose beads (Vector Laboratories, Burlingame, CA). The lectin-glycoprotein complexes were collected by centrifugation, washed with lysis buffer, and released from the bead complexes by boiling in SDS-PAGE sample buffer. Precipitated proteins were resolved by reducing SDS-PAGE, and immunoblotted to detect β1 integrin.
Stable ST6Gal-I transduction of OV4 cells
An ST6Gal-I cDNA construct, containing a C-terminal V5 tag, was a generous gift from Dr. Karen Colley (University of Illinois, Chicago). This construct was incorporated into a lentiviral vector containing a puromycin-resistance cassette for selection of stably-transduced cells, as previously described . OV4 cells were transduced with the ST6Gal-I lentivirus, and a pooled population of stable clones was obtained by puromycin selection. As a control, OV4 cells were transduced with a lentiviral construct lacking ST6Gal-I ("empty vector" cells). Stable expression of ST6Gal-I was confirmed by immunoblotting for ST6Gal-I, as well as the V5 tag.
Cell adhesion assay
The parental (P), ST6Gal-I-expressing (ST6), and empty vector-transduced (EV) cells were cultured in serum-free DMEM/F12 media for 48 hours. Cells were disengaged from the culture flasks using CellStripper solution (Cellgro, Herndon, VA) and 8 × 104 cells were plated onto culture dishes pretreated with 20 μg/mL bovine collagen I and blocked with 2% denatured bovine serum albumin (dBSA). To control for nonspecific binding, cells were also plated onto dishes pretreated with dBSA alone. Cells were allowed to adhere for 30 minutes at 37°C, and then samples were washed gently with PBS. The remaining adherent cells were fixed using formaldehyde and 4% sucrose, and subsequently stained with crystal violet and solubilized with 10% acetic acid. Absorbance of the solution dye was measured at 540 nm.
Haptotactic collagen I cell migration assay
P, ST6, and EV cells were cultured in serum-free media for 48 hours and disengaged from the culture dishes using CellStripper solution. 2.5 × 105cells were then seeded into the upper wells of Boyden chambers included in the QCM Collagen I Quantitative Cell Migration Assay Kit (Chemicon International). The chambers were lined with 8.0 μm polyethylene terpthalate (PET) membranes coated on the underside with a collagen I concentration gradient. To control for nonspecific migration, cells were also seeded into Boyden chambers with PET membranes coated with BSA. The lower chambers contained 300 μL of conditioned, serum-free NIH3T3 media for the chemoattractant. Cells were allowed to incubate at 37°C for 14 hours, and migration to the underside of the membrane was quantified as per the vendor's staining protocol.
Cell invasion assay
P, ST6, and EV cells were cultured in serum-free DMEM/F12 media for 48 hours prior to being disengaged from the culture flasks using CellStripper solution. BD BioCoat Growth Factor Reduced (GFR) Matrigel Invasion Chamber (BD Biosciences, San Jose, CA) assay kits were used to measure invasion. 5 × 105 cells were seeded into the upper wells of Boyden chambers lined with 8.0 μm PET membranes with a thin layer of GFR Matrigel Basement Membrane Matrix. The lower chamber contained 300 μL of conditioned, serum-free NIH3T3 media for the chemoattractant. Cells were incubated at 37°C for 48 hours, and invasion was quantified as per the vendor's staining protocol.
A screen of three ovarian carcinoma cell lines reveals differing levels of ST6Gal-I expression
The level of expression of ST6Gal-I is predictive of β1 integrin hypersialylation
Forced expression of ST6Gal-I in OV4
In order to demonstrate that the ST6Gal-I construct was functionally active, SNA was used to precipitate α2–6 sialylated glycoproteins as described above. The precipitates were then Western blotted for the β1 integrin, and, as expected, only the β1 integrins from ST6Gal-I expressing cells were found to be α2–6 sialylated (Fig 3B).
Cells expressing ST6Gal-I show greater adhesion to collagen I
Cells expressing ST6Gal-I show increased haptotactic migration on collagen I
Cells expressing ST6Gal-I show increased invasion
To determine whether up-regulated ST6Gal-I confers a more invasive phenotype, a cell invasion assay was run. More specifically, cells were applied to the top of a layer of growth-factor reduced Matrigel, coated on the top of a transwell filter. Cells were seeded in serum-free media, with conditioned NIH 3T3 media in the lower chamber as a chemoattractant. Cells were allowed to invade for 48 hours, and the cells migrating through the Matrigel to the underside of the filter were quantified. As shown in Fig. 5B, the ST6 cells were more invasive than either P (p < 0.05), or EV (p < 0.05). No difference was observed in the invasiveness of P and EV cells.
Peritoneal metastasis of epithelial ovarian carcinoma is the primary means of metastatic spread, although a small minority of tumors disseminate via hematogenous or lymphatic routes. At the time of diagnosis, about 70% of patients will have peritoneal spread of the disease, indicative of advanced stage (III-IV), which confers a worse prognosis than if the disease were discovered at an earlier stage. Though the process of peritoneal seeding is poorly understood, the most widely accepted hypothesis is that cells detach from the primary tumor, and are transported via peritoneal fluid throughout the abdomen, eventually attaching themselves to the peritoneal surface. Phenotypically, the tumor cells with the best chance of metastasizing are cells with the ability to escape apoptosis following detachment, while exhibiting increased capacity to adhere to, and invade through the peritoneum, which is exactly the cellular phenotype routinely seen in advanced stage ovarian carcinoma . In the present study, we show that forced expression of ST6Gal-I in ovarian epithelial cells, resulting in α2–6 sialylation of β1 integrins, induces increased adhesion and migration on collagen I and invasion through Matrigel. These results suggest that upregulation of ST6Gal-I in ovarian carcinoma may confer a more metastatic phenotype, which mirrors the findings of others' work with colon and breast cancers [13, 12].
The regulation of ST6Gal-I expression is multifactorial. Its expression is increased by oncogenic ras [9–11], though a ras mutation is only present in approximately 6% of epithelial ovarian cancers . However, even in the absence of a ras mutation, perturbations in the ras signaling pathway can lead to physiologically activated H-ras, which can be present in as much as 60% of ovarian tumors . Cytokines, such as TNF-α, IL-1, and IL-6, can also induce expression of ST6Gal-I [25, 26], and interestingly, IL-1 and IL-6 have been shown to increase ovarian carcinoma cell motility and metastasis, as well as being able to up-regulate TNF-α production [27, 28]. Finally, there are data to suggest that steroidal regulation of ST6Gal-I may be of importance in ovarian cancer. Corticosteroids up-regulate α2–6 sialyltransferase activity in vivo [29, 30], and increase ST6Gal-I mRNA expression in vitro . Further, cortisol has been shown to increase invasiveness in the SKOV3 cell line in vitro . Estradiol (E2) decreases ST6Gal-I expression in a dose dependent fashion in the human breast cancer cell line, MCF-7, an effect reversed with Tamoxifen . A lack of responsiveness to E2 in ovarian cancers has been demonstrated in SKOV3 to be due to a mutation in estrogen receptor-α , and thus is a plausible explanation for the hypersialylated phenotype despite an estrogenic microenvironment. Based on our findings in the present study, α2–6-hypersialylation may contribute to the invasive phenotype induced by these various modalities by altering the function of the β1 integrin receptor.
We have previously shown that ST6Gal-I-mediated sialylation of β1 integrins expressed by colon tumor cells increases cell adhesion to, and migration on collagen I . Likewise, α2–6 sialylation of purified integrin receptors enhances receptor binding to collagen I, confirming a critical role for sialylation in regulating integrin function. Collagen I has been shown to be secreted in vitro by LP9 mesothelial cells, along with fibronectin, laminin, vitronectin, and collagen types III and IV. In vivo, these molecules would contribute to the make up of the extracellular matrix (ECM) that free floating ovarian carcinoma cells would encounter, adhere to, and subsequently invade . β1 integrin's importance in the metastasis of ovarian cancer has been repeatedly demonstrated. β1 integrin is integral to multicellular spheroid formation , adhesion to peritoneal mesothelium [35, 37], migration toward a variety of ECM molecules , and spheroid disaggregation and invasion . Most studies of altered β1 function have focused on either changes in integrin expression or regulation of activity through "inside-out" signaling mechanisms (e.g., conformational changes elicited by the binding of cytosolic molecules to integrin cytoplasmic tails). However, there is growing appreciation for the role of variant sialylation in modulating β1 activity.
Given the extensive evidence of hypersialylation in tumor progression, sialyltransferases have been investigated as potential targets for drug therapy . ST6Gal-I acts to catalyze the transfer of the activated sialyl residue from a sugar nucleotide donor to a glycoconjugate acceptor. Strategies designed to halt this process can be aimed at competitively inhibiting the donor with a sugar nucleotide analog, or with an analog of the transition state which binds with many order higher affinity to sialyltransferases than do ground state analogs , or by inhibiting the acceptor with a glucoconjugate analog. Another promising avenue of sialyltransferase inhibition is with antisense-oligodeoxynucleotides, which reduce cell surface sialylation without affecting overall cell viability or growth . Challenges remain in developing a sialyltransferase inhibitor that is readily bioavailable, but several strategies to circumvent these problems are under investigation.
In this study, we have shown that cell behaviors consistent with a metastatic phenotype can be induced in ovarian tumor cells by upregulation of ST6Gal-I, with consequent α2–6 sialylation of β1 integrins. Overexpression of ST6Gal-I has previously been implicated in colorectal and breast adenocarcinomas, however, only limited information has been available regarding the role of this enzyme in ovarian cancer. The accumulating evidence indicating that ST6Gal-I-mediated integrin sialylation causes increased cell migration and invasion in multiple tumor types suggests that ST6Gal-I is a promising target for therapeutic intervention.
This investigation was supported by NIH grant R01CA84248 (SLB).
- Varki NM, Varki A: Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 2007, 87: 851–857. 10.1038/labinvest.3700656PubMedView ArticleGoogle Scholar
- Bellis SL: Variant glycosylation: an underappreciated regulatory mechanism for beta1 integrins. Biochim Biophys Acta 2004, 1663: 52–60. 10.1016/j.bbamem.2004.03.012PubMedView ArticleGoogle Scholar
- Dall'Olio F: The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and functional role. Glycoconj J 2000, 17: 669–676. 10.1023/A:1011077000164PubMedView ArticleGoogle Scholar
- Dall'Olio F, Chiricolo M, Lau JT: Differential expression of the hepatic transcript of beta-galactoside alpha2,6-sialyltransferase in human colon cancer cell lines. Int J Cancer 1999, 81: 243–247. 10.1002/(SICI)1097-0215(19990412)81:2<243::AID-IJC13>3.0.CO;2-OPubMedView ArticleGoogle Scholar
- Wang PH, Lee WL, Lee YR, Juang CM, Chen YJ, Chao HT, Tsai YC, Yuan CC: Enhanced expression of alpha 2,6-sialyltransferase ST6Gal I in cervical squamous cell carcinoma. Gynecol Oncol 2003, 89: 395–401. 10.1016/S0090-8258(03)00127-6PubMedView ArticleGoogle Scholar
- Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P: Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res 1998, 58: 4066–4070.PubMedGoogle Scholar
- Pousset D, Piller V, Bureaud N, Monsigny M, Piller F: Increased alpha2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma. Cancer Res 1997, 57: 4249–4256.PubMedGoogle Scholar
- Bergler W, Riedel F, Schwartz-Albiez R, Gross HJ, Hormann K: A new histobiochemical method to analyze sialylation on cell-surface glycoproteins of head and neck squamous-cell carcinomas. Eur Arch Otorhinolaryngol 1997, 254: 437–441. 10.1007/BF02439975PubMedView ArticleGoogle Scholar
- Dalziel M, Dall'Olio F, Mungul A, Piller V, Piller F: Ras oncogene induces beta-galactoside alpha2,6-sialyltransferase (ST6Gal I) via a RalGEF-mediated signal to its housekeeping promoter. Eur J Biochem 2004, 271: 3623–3634. 10.1111/j.1432-1033.2004.04284.xPubMedView ArticleGoogle Scholar
- Le Marer N, Laudet V, Svensson EC, Cazlaris H, Van Hille B, Lagrou C, Stehelin D, Montreuil J, Verbert A, Delannoy P: The c-Ha-ras oncogene induces increased expression of beta-galactoside alpha-2, 6-sialyltransferase in rat fibroblast (FR3T3) cells. Glycobiology 1992, 2: 49–56. 10.1093/glycob/2.1.49PubMedView ArticleGoogle Scholar
- Seales EC, Jurado GA, Singhal A, Bellis SL: Ras oncogene directs expression of a differentially sialylated, functionally altered beta1 integrin. Oncogene 2003, 22: 7137–7145. 10.1038/sj.onc.1206834PubMedView ArticleGoogle Scholar
- Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL: Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res 2005, 65: 4645–4652. 10.1158/0008-5472.CAN-04-3117PubMedView ArticleGoogle Scholar
- Lin S, Kemmner W, Grigull S, Schlag PM: Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp Cell Res 2002, 276: 101–110. 10.1006/excr.2002.5521PubMedView ArticleGoogle Scholar
- Zhu Y, Srivatana U, Ullah A, Gagneja H, Berenson CS, Lance P: Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim Biophys Acta 2001, 1536: 148–160.PubMedView ArticleGoogle Scholar
- Lise M, Belluco C, Perera SP, Patel R, Thomas P, Ganguly A: Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients. Hybridoma 2000, 19: 281–286. 10.1089/027245700429828PubMedView ArticleGoogle Scholar
- Poon TC, Chiu CH, Lai PB, Mok TS, Zee B, Chan AT, Sung JJ, Johnson PJ: Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma. World J Gastroenterol 2005, 11: 6701–6706.PubMed CentralPubMedGoogle Scholar
- Vazquez-Martin C, Gil-Martin E, Fernandez-Briera A: Elevation of ST6Gal I activity in malignant and transitional tissue in human colorectal cancer. Oncology 2005, 69: 436–444. 10.1159/000089999PubMedView ArticleGoogle Scholar
- Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, Banks RE, Hutson R, Harvey DJ, Antrobus R, Petrescu SM, Dwek RA, Rudd PM: Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007, 17: 1344–1356. 10.1093/glycob/cwm100PubMedView ArticleGoogle Scholar
- Wang PH, Lee WL, Juang CM, Yang YH, Lo WH, Lai CR, Hsieh SL, Yuan CC: Altered mRNA expressions of sialyltransferases in ovarian cancers. Gynecol Oncol 2005, 99: 631–639. 10.1016/j.ygyno.2005.07.016PubMedView ArticleGoogle Scholar
- Casey RC, Oegema TR Jr, Skubitz KM, Pambuccian SE, Grindle SM, Skubitz AP: Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells. Clin Exp Metastasis 2003, 20: 143–152. 10.1023/A:1022670501667PubMedView ArticleGoogle Scholar
- Semel AC, Seales EC, Singhal A, Eklund EA, Colley KJ, Bellis SL: Hyposialylation of integrins stimulates the activity of myeloid fibronectin receptors. J Biol Chem 2002, 277: 32830–32836. 10.1074/jbc.M202493200PubMedView ArticleGoogle Scholar
- Lee JM, Dedhar S, Kalluri R, Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172: 973–981. 10.1083/jcb.200601018PubMed CentralPubMedView ArticleGoogle Scholar
- Varras MN, Sourvinos G, Diakomanolis E, Koumantakis E, Flouris GA, Lekka-Katsouli J, Michalas S, Spandidos DA: Detection and clinical correlations of ras gene mutations in human ovarian tumors. Oncology 1999, 56: 89–96. 10.1159/000011946PubMedView ArticleGoogle Scholar
- Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast RC Jr, Ostrowski MC: Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 1998, 58: 2253–2259.PubMedGoogle Scholar
- Dalziel M, Lemaire S, Ewing J, Kobayashi L, Lau JT: Hepatic acute phase induction of murine beta-galactoside alpha 2,6 sialyltransferase (ST6Gal I) is IL-6 dependent and mediated by elevation of exon H-containing class of transcripts. Glycobiology 1999, 9: 1003–1008. 10.1093/glycob/9.10.1003PubMedView ArticleGoogle Scholar
- Hanasaki K, Varki A, Stamenkovic I, Bevilacqua MP: Cytokine-induced beta-galactoside alpha-2,6-sialyltransferase in human endothelial cells mediates alpha 2,6-sialylation of adhesion molecules and CD22 ligands. J Biol Chem 1994, 269: 10637–10643.PubMedGoogle Scholar
- Malik S, Balkwill F: Epithelial ovarian cancer: a cytokine propelled disease? Br J Cancer 1991, 64: 617–620.PubMed CentralPubMedView ArticleGoogle Scholar
- Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Muller-Holzner E, Offner F, Feichtinger H, Zwierzina H, Daxenbichler G: Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 1996, 67: 826–830. 10.1002/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#PubMedView ArticleGoogle Scholar
- Maguire TM, Coughlan CM, Seckl JR, Breen KC: The effect of corticosteroids on serum sialyltransferase enzyme activities in the rat. Biochim Biophys Acta 1998, 1379: 23–28.PubMedView ArticleGoogle Scholar
- Wang XC, Smith TJ, Lau JT: Transcriptional regulation of the liver beta-galactoside alpha 2,6-sialyltransferase by glucocorticoids. J Biol Chem 1990, 265: 17849–17853.PubMedGoogle Scholar
- Vandamme V, Pierce A, Verbert A, Delannoy P: Transcriptional induction of beta-galactoside alpha-2,6-sialyltransferase in rat fibroblast by dexamethasone. Eur J Biochem 1993, 211: 135–140. 10.1111/j.1432-1033.1993.tb19879.xPubMedView ArticleGoogle Scholar
- Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW: Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006, 12: 369–375. 10.1158/1078-0432.CCR-05-1698PubMed CentralPubMedView ArticleGoogle Scholar
- Peyrat JP, Recchi MA, Hebbar M, Pawlowski V, Hornez L, Dong-Lebouhris X, Hondermarck H, Harduin-Lepers A, Delannoy P: Regulation of sialyltransferase expression by estradiol and 4-OH-tamoxifen in the human breast cancer cell MCF-7. Mol Cell Biol Res Commun 2000, 3: 48–52. 10.1006/mcbr.2000.0185PubMedView ArticleGoogle Scholar
- Lau KM, Mok SC, Ho SM: Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 1999, 96: 5722–5727. 10.1073/pnas.96.10.5722PubMed CentralPubMedView ArticleGoogle Scholar
- Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP: CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol 1999, 154: 1525–1537.PubMed CentralPubMedView ArticleGoogle Scholar
- Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR Jr, Ruff LE, Skubitz AP: Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 2001, 159: 2071–2080.PubMed CentralPubMedView ArticleGoogle Scholar
- Strobel T, Cannistra SA: Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 1999, 73: 362–367. 10.1006/gyno.1999.5388PubMedView ArticleGoogle Scholar
- Casey RC, Skubitz AP: CD44 and beta1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clin Exp Metastasis 2000, 18: 67–75. 10.1023/A:1026519016213PubMedView ArticleGoogle Scholar
- Burleson KM, Hansen LK, Skubitz AP: Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis 2004, 21: 685–697. 10.1007/s10585-004-5768-5PubMedView ArticleGoogle Scholar
- Wang X, Zhang LH, Ye XS: Recent development in the design of sialyltransferase inhibitors. Med Res Rev 2003, 23: 32–47. 10.1002/med.10030PubMedView ArticleGoogle Scholar
- Wolfenden R, Frick L: Transition state affinity and the design of enzyme inhibitors. In Enzyme Mechanisms. Edited by: Page M, Williams A. London: The Royal Society of Chemistry; 1987:97–122.Google Scholar
- Kemmner W, Hohaus K, Schlag PM: Inhibition of Gal beta1, 4GlcNAc alpha2,6 sialyltransferase expression by antisense-oligodeoxynucleotides. FEBS Lett 1997, 409: 347–350. 10.1016/S0014-5793(97)00543-7PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.